Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.
Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback